skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

In withdrawing its European marketing application for Translarna in cystic fibrosis, PTC Therapeutics has bid farewell to a market opportunity once pegged at $700m.

 

PTC Therapeutics Inc. has withdrawn its European marketing authorization application for Translarna (ataluren) in nonsense mutation cystic fibrosis following its failure in a pivotal Phase III trial. Translarna’s CF failure could mean a lost opportunity of at least $700m in the US and the five biggest EU markets.

 

PTC has called time on pursuing marketing authorization for Translana as a treatment for nonsense mutation cystic fibrosis (nmCF). The European Medicines Agency announced on Mar 24, 2017 that that the company had withdrawn its marketing authorization application at the beginning of the month. However, the move comes as no surprise after the drug failed to perform in the ACT CF trial, which prompted PTC to announce it would no longer be pursuing Translana as a CF treatment (Also see "PTC Tumbles On Ataluren Failure In Cystic Fibrosis" - Scrip, 2 Mar, 2017.). There was a small treatment effect with Translarna, but it failed to significantly improve pulmonary measures compared to placebo.

 

Datamonitor Healthcare analyst Daniel Chancellor believes Translana’s CF failure is a blow for this subset of patients, which make up around 10% of the total. The drug would have met a key unmet need, and at present there is nothing else in active development for these patients. He also notes that Translarna was the only ribosomal readthrough stimulant in development. Furthermore, Translarna in CF could have earned $707m for the company by 2025 in the US and EU big five markets, according to Datamonitor Healthcare estimates.

 

Nevertheless, Translarna already has conditional EU approval for treating nonsense mutation Duchenne muscular dystrophy and is performing well, with a German list price of around €440,000 ($488,000) per year. According to PTC’s annual report, the drug earned $81.4m in net product sales in 2016, up significantly from net sales worth $33.7m in 2015. PTC is also pursuing US approval for treating nmDMD and says the US FDA has granted a standard review and assigned a PDUFA date of October 24, 2017.

 

According to Chancellor, all eyes will now turn to Vertex Pharmaceuticals Inc. and its VX-661/ivacaftor (tezacaftor/ivacaftor) regimen. Several Phase III trials are scheduled to complete during 2017. This combination pill could potentially provide a genotype-specific drug to patients with one copy of the F508del mutation, which is the most common cystic fibrosis-causing mutation. Vertex currently markets Kalydeco (ivacaftor) for patients with gating mutations and Orkambi (lumacaftor/ivacaftor) for homozygous F508del patients.

 

Editor’s note: For more information, see Datamonitor Healthcare ’s latest analyst opinion on Translarna.

Read also

  • Biomedtracker: follow the drug development process

    Biomedtracker 2018 Early Outlook Report

    What's on the horizon for pharma in 2018? Find out with Biomedtracker&rsquo;s Early 2018 Outlook Report extract. Download free extracts from this essential report, which investigates the catalysts expected to occur in the first part of the year for 21 different drugs.<br />

    Topics Drug development landscape

  • Biomedtracker: follow the drug development process

    Accurate, Intuitive and Updated In Real Time

    03 Apr 2017

    Learn why pharmaceutical, biotech, and investment companies rely on BioMedTracker for its insight on the likelihood of approval, commercial potential, and future data and regulatory catalysts for drugs within the competitive landscape of every important disease and indication.

  • Scrip: industry news and insights

    Hong Kong Takes On Nasdaq For China Biotech IPOs

    By Brian Yang

    <span style="color: #58595b; text-align: start; letter-spacing: normal;">Hong Kong is catching global attention as it plans to drastically change listing rules for biotech firms, potentially opening the way to both Chinese companies seeking public funding and international firms eyeing entry to China. A Shanghai biosimilars developer, among others, is now eyeing an offering.</span>

    Topics Policy and regulation

;

Next steps

Whether you’re a small biotech start-up, research firm, generic manufacturer or a global pharmaceutical giant, you need focused, independent insight and opinion on market developments.

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888 670 8900
  • US Toll           : +1 908 547 2200
  • UK & Europe : +44 (20) 337 73737
  • Australia        : +61 2 8705 6907
  • Japan              : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: